Современные принципы профилактической терапии мигрени у детей и подростков


Ю.Е. Нестеровский, Н.Н. Заваденко

Кафедра неврологии, нейрохирургии и медицинской генетики ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России, Москва
Мигрень у детей и подростков влияет на качество жизни не только ребенка, но и его семьи в целом. Выбор лечебной тактики должен осуществляться с учетом возраста, особенностей течения заболевания, сопутствующих заболеваний, индивидуальных особенностей пациента и сочетать как лекарственные, так и немедикаментозные методы терапии. Профилактическая терапия мигрени направлена на улучшение состояния больного и позволяет избегать или уменьшать прогрессирование болезни в более зрелом возрасте. В настоящее время достаточной доказательной базой эффективности профилактической терапии обладают такие препараты, как амитриптилин, топирамат, вальпроевая кислота. Нутрицевтики являются альтернативным вариантом профилактического лечения мигрени у детей и могут быть предложены в тех случаях, когда родители не соглашаются на прием традиционных лекарственных препаратов. Имеются публикации об эффективности коэнзима Q10 и рибофлавина в профилактическом лечении мигрени у детей. Также эффективность лекарственной терапии у детей повышается при дополнительном применении методов немедикаментозного воздействия.

Литература


  1. Lewis D.W. Pediatric migraine. Neurol Clin. 2009;27:481–501.
  2. Hershey A.D. Pediatric headache: update on recent research. Headache. 2012;52(2):327–32.
  3. Stewart W.F., Linet M.S., Celentano D.D., Van Natta M., Siegler D. Age and sex-specific incidence rates of migraine with and without visual aura. Am. J. Epidemiol. 1991;34:1111–20.
  4. Diamond S., Bigal M.E., Silberstein S., et al. Patterns of diagnosis and acute and preventative treatment of migraine in the United States. Results of the American Migraine Prevalence and Prevention Study. Headache. 2007;47(9):355–63.
  5. Aydin M., Kabakus N., Bozdag S., Ertugrul S. Profile of children with migraine. Indian J. Pediatr. 2010;77:1247–51.
  6. Bruijn J., Arts W.F., Duivenvoorden H., Dijkstra N., Raat H., Passchier J. Quality of life in children with primary headache in a general hospital. Cephalalgia. 2009;29(Issue 6):624–30.
  7. Stang P.E., Osterhaus J.T. Impact of migraine in the United States: data from the International Health Interview Survey. Headache. 1993;33:29–35.
  8. Powers S.W., Patton S.R., Hommel K.A., Hershey A.D. Quality of life in paediatric migraine: haracterization of age-related effects using Peds QL 4.0. Cephalalgia. 2004;24:120–27.
  9. Hershey A.D. Current approaches to the diagnosis and management of pediatric migraine. Lancet Neurology. 2010;9:190–204.
  10. Lewis D.W., Diamond S., Scott D., Jones V. Prophylactic treatment of pediatric migraine. Headache. 2004;44(3):230–37.
  11. Abu-Arafeh I. Childhood Headache. 2nd Edition. London: Mac Keith Press, 2013.
  12. Couch J.R., Zeigler D.K., Hassanein R. Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects. Neurology. 1976;26:121–27.
  13. Papetti L., Spalice A., Nicita F., Paolino M.C., Castaldo R., Iannetti P., Villa M.P., Parisi P. Migraine treatment in the developmental age: guidelines update. J. Headache Pain. 2010;11(3):267–76.
  14. Hershey A.D., Powers S.W., Bentii A.L., deGrauw T.J. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache. 2000;40:539–49.
  15. Eidlitz-Markus T., Dlugatch Y., Haimi-Cohen Y., Goldberg-Stern H., Zeharia A. Nonpharmacologic treatment of migraine with lowdose propranolol or amitriptyline. Pediatr. Neurol. 2012;46:345–49.
  16. Lewis D., Winner P., Saper J., Ness S., Polverejan E., Wang S., Kurland C.L., Nye J., Yuen E., Eerdekens M., Ford L. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics. 2009;123(3):924–34.
  17. Winner P., Gendolla A., Stayer C., Wang S., Yuen E., Battisti W.P., Nye J.S. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache. 2006;46:1503–10.
  18. O’Brien H.L., Kabbouche M.A., Hershey A.D. Treating pediatric migraine: an expert opinion. Expert Opin Pharmacother. 2012;13(7):959–66.
  19. Unalp A., Uran N., Ozturk A. Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine. J. Child. Neurol. 2008;23:1377–81.
  20. Apostol G., Lewis D., Laforet G.A., Robieson W.Z., Fugate J.M., AbiSaab W.M., Salterelli M.D. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache. 2009;49(1):45–53.
  21. Bidabadi E., Mashouf M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatr Drugs. 2010;54(3):269–75.
  22. Miller G.S. Efficacy and safety of levetiracetam in pediatric migraine. Headache. 2004;44:238–43.
  23. Pakalnis A., Kring D., Meier L. Levetiracetam prophylaxis in pediatric migraine – an open-label study. Headache. 2007;43(3):427–30.
  24. Pakalnis A., Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache. 2006;46(5):804–7.
  25. Silberstein S., Goode-Sellers S., Twomey C., Saiers J, Ascher J. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia. 2012;33(2):101–11.
  26. Belman A.L., Milazo M., Savatic M. Gabapentin for migraine prophylaxis in children. Ann Neurol. 2001;50(Suppl 1):S109.
  27. Johnson A., Bickel J., Lebel A. Pediatric migraine prescription patterns at a large academic hospital. Pediatr Neurol. 2014;51: 706–12.
  28. Termine C., Ozge A., Antonaci F., Natriashvili S., Guidetti V., Wober-Bingol C. Overview of diagnosis and management of paediatric headache. Part II: therapeutic management. J. Headache Pain. 2011;12(1):25–34.
  29. Symon D.N., Russell G. Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine. Arch. Dis. Child. 1995;72(1):48–50.
  30. Ludvigsson J. Propranolol used in prophylaxis of migraine in children. Acta Neurologica. 1974;50:109–15.
  31. Lewis D., Ashwal S., Hershey A., Hirtz D., Yonker M., Silberstein S. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American academy of neurology quality standards subcommittee and the practice committee of the child neurology society. Neurology. 2004;63:2215–24.
  32. Forsythe W.I., Gillies D., Sills M.A. Propanolol (‘Inderal’) in the treatment of childhood migraine. Dev Med Child Neurol. 1984;26:737–41.
  33. Evers S., Afra J., Frese A., Goadsby P.J., Linde M., May A., Sándor P.S. EFNS guideline on the drug treatment of migraine – report of an EFNS task force. Eur. J. Neurol. 2006;13(6):560–72.
  34. Sorge F., De Simone R., Marano E., Nolano M., Orefice G., Carrieri P. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study. Cephalalgia. 1988;8(1):1–6.
  35. Peer Mohamed B., Goadsby P.J., Prabhakar P. Safety and efficacy of flunarizine in childhood migraine: 11 years’ experience, with emphasis on its effect in hemiplegic migraine. Dev. Med. Child Neurol. 2012;54(3):274–77.
  36. Bernhard M.K., Bertsche A., Syrbe S., Weise S., Merkenschlager A. Botulinum toxin injections for chronic migraine in adolescents – an early therapeutic option in the transition from neuropaediatrics to neurology. Fortschr Neurol. Psychiatr. 2014;82(1):39–42.
  37. Ahmed K., Oas K.H., Mack K.J., Garza I. Experience with botulinum toxin A in medically intractable pediatric chronic daily headache. Pediatr Neurol. 2010;43(5):316–19.
  38. Sándor P.S., Di Clemente L., Coppola G., Saenger U., Fumal A., Magis D., Seidel L., Agosti R.M., Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713–15.
  39. Orr S., Venkateswaran S. Neutraceuticals in the prophylaxis of pediatric migraine: Evidence-based review and recommendations. Cephalalgia. 2014;34(8):568–83.
  40. Hershey A.D., Powers S.W., Vockel A.L., Lecates S.L., Ellinor S.L., Segers A., Burdine D., Manning P., Kabbouche M.A. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007;47(1):73–80.
  41. Slater S.K., Nelson T.D., Kabbouche M.A., Lecates S.L., Horn P., Segers A., Manning P., Powers S.W., Hershey A.D. A randomized, double-blinded, placebo-controlled, crossover, add on study of coenzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2010;31(8):897–905.
  42. Condo M., Posar A., Arbizzani A., Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain. 2009;10(5):361–65.
  43. Peikert A., Wilimzig C., Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16(4):257–63.
  44. Holland S., Silberstein S.D., Freitag F., Dodick D.W., Argoff C., Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. 2012;78:1346–53.
  45. Gallai V., Sarchielli P., Coata G., Firenze C., Morucci P., Abbritti G. Serum and salivary magnesium levels in migraine. Results in a group of juvenile patients. Headache. 1992;32(3):132–35.
  46. Wang F., Van Den Eeden S.K., Ackerson L.M., Salk S.E., Reince R.H., Elin R.J. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache. 2003;43:601–10.
  47. Blume H.K., Brockman L.N., Breuner C.C. Biofeedback therapy for pediatric headache: factors associated with response. Headache. 2012;52(9):1377–86.
  48. Powers S.W., Mitchell M.J., Byars K.C., Bentti A.L., LeCates S.L., Hershey A.D. A pilot study of one-session biofeedback training in pediatric headache. Neurology. 2001;56(1):133.
  49. Eidlitz-Markus T., Haimi-Cohen Y., Steier D., Zeharia A. Effectiveness of nonpharmacologic treatment for migraine in young children. Headache. 2010;50:219–23.
  50. Bruni O., Galli F., Guidetti V. Sleep hygiene and migraine in children and adolescents. Cephalalgia. 1999;19(Suppl 25):57–9.
  51. Millichap J.G., Ye M.M. The diet factor in pediatric and adolescent migraine. Pediatr Neurol. 2003;28:9–15.


Об авторах / Для корреспонденции


Н.Н. Заваденко – д.м.н., проф., зав. кафедрой неврологии, нейрохирургии и медицинской генетики ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России, Москва; e-mail: zavadenko@mail.ru


Похожие статьи


Бионика Медиа